Brought to you by 
Astellas gets rights to Ironwood's linaclotide in Pacific Rim
31 Oct 2019
Executive Summary
Ironwood Pharmaceuticals has licensed Japanese pharmaco Astellas Pharma exclusive rights to develop and commercialize its lead compound linaclotide in Japan, Indonesia, Korea, the Philippines, Taiwan, and Thailand.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Astellas gets rights to Ironwood's linaclotide in Pacific Rim
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice